Clinical Trial Update: EGFR-TKI With/Without Chemotherapy in NSCLC Patients With Both EGFR Mutation and BIM Deletion Polymorphism [Phase 2]

View source ↗

Summary

This Phase 2 trial is evaluating whether adding chemotherapy to an EGFR tyrosine kinase inhibitor improves outcomes in non-small cell lung cancer patients with …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Snippet

Sponsor: Shanghai Pulmonary Hospital, Shanghai, China | Conditions: Nonsmall Cell Lung Cancer, EGFR Gene Mutation | Phase 2 | Status: UNKNOWN